Excerpt: What is the status of DOC-IG investigative performance? Has it been improving or declining? Has it been affected by controversies and disputes between some current or former DOC law enforcement agents and the DOC-IG management? Has performance been affected by certain personnel practices?; To read the letter, click here.
Excerpt: It is our understanding that the NRC has a track record of producing cost estimates for its requirements on nuclear power reactors that can be egregiously off target from the actual costs of implementing the requirements. To read the letter, click here.
To read EPA's May 15, 2013, response, click here.
Exceprt: Since the week of February 18, 2013, through the last available listing in April 2013, the FDA's Public Calendar has listed Dr. Brenner-Gati as the Acting Deputy Commissioner for Medical Products and Tobacco with no significant meetings. However, the FDA posted on its website the FDA organizational chart approved and signed on March 4, 2013, by the FDA Reorganization Coordinator listing the position of Deputy Commissioner for Medical Products as vacant.
To read the letter to HHS, click here. To read the letter to the following companies, click here.
Exceprt: The award —at $100.6 million, one of the largest broadband grants under the ARRA — has been a source of controversy. The grant to EAGLE-Net Alliance, originally made to the Colorado Centennial Board of Cooperative Educational Services and subsequently transferred to EAGLE-Net, has been criticized for overbuilding existing infrastructure rather than delivering service to unserved communities.